Compare TBBK & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | SLNO |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2005 | 2014 |
| Metric | TBBK | SLNO |
|---|---|---|
| Price | $52.75 | $52.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $69.00 | ★ $83.00 |
| AVG Volume (30 Days) | 382.4K | ★ 2.0M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.69 | ★ 108.90 |
| EPS | ★ 1.41 | 0.59 |
| Revenue | ★ $141,147,000.00 | $1,450,788.00 |
| Revenue This Year | N/A | $150.46 |
| Revenue Next Year | $8.16 | $50.37 |
| P/E Ratio | ★ $38.07 | $89.71 |
| Revenue Growth | 20.85 | ★ 138.82 |
| 52 Week Low | $48.86 | $29.43 |
| 52 Week High | $81.65 | $89.12 |
| Indicator | TBBK | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 77.12 |
| Support Level | $50.85 | $48.91 |
| Resistance Level | $55.74 | $55.47 |
| Average True Range (ATR) | 1.99 | 0.07 |
| MACD | -0.93 | -0.55 |
| Stochastic Oscillator | 5.07 | 92.73 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.